"Soligenix Achieves Breakthrough in Nonhuman Primate Protection Against Ebola and Marburg Viruses"

Soligenix, Inc., in collaboration with the University of Hawaiʻi, has published a study demonstrating a novel, single-vial, bivalent vaccine that provides 100% protection against Sudan ebolavirus and Marburg marburgvirus in nonhuman primate models. This thermostabilized vaccine, which remains stable at high temperatures, could significantly improve responses to outbreaks due to its ease of storage and transportation. The vaccine's development is supported by NIH and SBIR grants, and it utilizes a platform that has been applied to other vaccine candidates, including those for ricin toxin and COVID-19.